Monoclonal antibodies (F36/22 and M7/105) to human breast carcinoma
Papsidero, L.D.; Croghan, G.A.; O'Connell, M.J.; Valenzuela, L.A.; Nemoto, T.; Chu, T.M.
Cancer Research 43(4): 1741-1747
1983
ISSN/ISBN: 0008-5472 PMID: 6339043 Document Number: 218586
Cloned hybridoma cell lines were obtained from fusions of murine myeloma cells with lymphocytes of mice immunized against human breast cancer cells. Hybridomas F36/22 and M7/105 produced antibodies whose binding to breast cancer cells could not be inhibited by prior absorptions with fibroblasts, lymphoblastoid cells, or erythrocytes. Results from cell surface binding assays using a panel of tumor cell lines indicated that antibodies F36/22 and M7/105 recognized determinants expressed maximally on breast cancer cells. Antibody F36/22 reacted with normal mammary epithelial membranes and milk fat globule membranes, whereas antibody M7/105 produced no detectable binding to these specimens. Antigens carrying these epitopes each showed reactivity with concanavalin A lectin. The determinant corresponding to antibody F36/22 was detectable in histological sections of a subset of breast tumors obtained at surgery.